Founded in 2004, ERYTECH is a clinical-stage biopharmaceutical developing innovative therapies for rare cancers and orphan diseases.
Leveraging its proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside red blood cells, ERYTECH developed a pipeline of product candidates targeting markets with unmet medical needs. ERYTECH’s focus is the treatment of blood cancers, including ALL and solid tumors, including pancreatic & triple negative breast cancers, by targeting amino acid metabolism and depriving tumors of nutrients necessary for survival.